• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Women s Health >Refractory fallopian tube carcinoma – current perspectives in pathogenesis and management
【24h】

Refractory fallopian tube carcinoma – current perspectives in pathogenesis and management

机译：难治性输卵管癌-发病机理和治疗的最新观点

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Fallopian tube carcinoma (FTC) is considered a rare malignancy, but recent evidence shows that its incidence may have been underestimated. Risk-reducing salpingo-oophorectomy (RRSO) in breast cancer susceptibility gene (BRCA)-positive women has provided a unique opportunity to study the pathogenesis of FTC and ovarian carcinomas. Newer data now suggest that most high-grade serous cancers of the ovary originate in the fimbrial end of the fallopian tube. Due to the presumed rarity of FTC, most current and more recent ovarian cancer clinical trials have now included patients with FTC. The treatment guidelines recommend similar overall management and that the same chemotherapy regimens be used for epithelial ovarian cancers and FTC.
机译：摘要：输卵管癌（FTC）被认为是一种罕见的恶性肿瘤，但最近的证据表明其发生率可能被低估了。乳腺癌易感基因（BRCA）阳性女性的降低风险的输卵管卵巢切除术（RRSO）为研究FTC和卵巢癌的发病机理提供了独特的机会。现在，最新的数据表明，大多数卵巢高级浆液性癌起源于输卵管的纤维末端。由于FTC的稀缺性，目前大多数最新的卵巢癌临床试验都包括FTC患者。该治疗指南建议采用类似的总体管理方法，并且对上皮性卵巢癌和FTC使用相同的化疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号